Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A recent publication in Nature Genetics, examined the effect of a gene called KLF14. The researchers, including Prof Mark McCarthy found that genetic variations that control KLF14 have little impact on overall weight but they have a marked impact on where in the body any excess fat is stored.

In women, versions of the gene that are result in fat being preferentially deposited around the hips, rather than around the abdomen, provide protection against diabetes.

Read the full article

Similar stories

Professor Sarah Gilbert awarded RSA Albert Medal

News

NDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts’ (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.

World’s largest clinical trial for COVID-19 treatments expands internationally

News

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join and recruited to RECOVERY International. NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health, and Joint Chief Investigator for the trial, said ‘The RECOVERY trial has been an enormous success, enrolling over 36,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies".

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

News

Exscientia, the leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).

Tocilizumab reduces deaths in patients hospitalised with COVID-19

News

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19.

Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests

News

Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.

Oxford Cancer Centre appoints Professor Tim Elliot as new co-director

News

The CRUK Oxford Centre is pleased to announce the appointment of Professor Tim Elliot as its new co-Director. Tim has recently joined the Nuffield Department of Medicine and Oriel College as the Kidani Professor of Immuno-Oncology. He re-joins the Oxford community from Southampton University, having previously completed his undergraduate degree in Biochemistry at Balliol and subsequently holding a Professorial post at the Weatherall Institute for Molecular Medicine.